South African·American Studies… “The antibodies formed in the past cannot mutate”
“In addition to antibodies, there are many elements of the immune system, so further tests need to be conducted”
(Seoul = Yonhap News) Reporter Ahn Yong-soo = Multiple studies have shown that antibodies generated after having an early novel coronavirus infection (Corona 19) or after being vaccinated may be susceptible to a mutant virus from South Africa.
This means that even if you get the COVID-19 vaccine, it doesn’t end at once, but whenever major mutations like the flu occur, you may need to develop a new vaccine and get an additional dose.
However, the test must be further conducted until the research results are verified.
The vaccine jointly developed by Bioentech and Pfizer has proven effective against mutant viruses originating in the UK, but there are no proven results for mutants in South Africa, the Wall Street Journal (WSJ) reported on the 22nd (local time).
As a new mutation emerges in the first year of the Corona 19 crisis, researchers around the world are also having difficulty tracking and identifying it.
In particular, concerns are growing when a mutant virus emerges in an area where a significant number of the population has been determined to have formed corona19 antibodies.
The mutant Corona 19 study was conducted by drawing blood from the corona 19 virus cultured in the laboratory and from subjects who were initially infected with Corona 19.
As the stage before the official paper is published, the results of clinical trials in the UK and South Africa within a few weeks will allow us to accurately determine how effective the vaccine is against mutant COVID-19, WSJ said.
To date, mutations originating in South Africa have been found in 22 countries including Canada, China and Germany.
Researchers in South Africa have confirmed that the mutant virus completely neutralizes or is rarely affected by antibodies formed by infection with Corona 19.
The study was conducted by confirming the antibody and mutant Corona 19 virus reaction results obtained from patients infected in the first outbreak.
Another study in South Africa focused on the mutant virus’s spike protein, and 21 out of 44 antibodies from early COVID-19 infections failed to fight the mutant virus.
It is said that only three types of antibodies extracted from severe corona19 patients in the past effectively blocked the mutant virus.
The researchers concluded that, along with the possibility of reinfection of Corona 19, the effectiveness of existing vaccines made by neutralizing the spike protein on the surface of the virus may be less effective.
Apart from the study in South Africa, Rockefeller University and California Institute of Technology conducted the study by extracting blood from Pfizer and Modena vaccinations.
Studies have shown that three major mutant viruses from South Africa can significantly reduce the effectiveness of antibodies formed by vaccination.
As a result, researchers in the United States said that the virus situation should continue to be reflected so that Pfizer’s and Modena’s vaccines do not become less effective.
Modena declined to express its position on the study, but it has revealed that it is analyzing the effectiveness of various mutant viruses.
Pfizer said it is working on a mutant virus (E484K) found in South Africa and Brazil, and will announce the results as they become available.
However, James Naismith, a professor at Oxford University, said, “The research in South Africa was done in a laboratory, so we have to observe the results in real situations.” “There are more elements that make up the immune system besides antibodies.”
Unauthorized reproduction-prohibition of redistribution>
2021/01/23 08:33 sent